ERBITUX with platinum-based chemotherapy and fluorouracil (CT) may help shrink your tumors.
Objective response rate
ERBITUX with CT was shown to shrink tumors (objective response rate) to at least half their combined size† in 35.6% of people compared to 19.5% of those treated with CT alone.
SELECT SAFETY INFORMATION
ERBITUX can cause lung disease. Lung disease occurred in less than 0.5% of 1570 patients receiving ERBITUX in clinical trials for colorectal cancer and head and neck cancer; 1 patient died.
- Notify your doctor if you develop shortness of breath, a new or worsening cough and/or chest pain while receiving ERBITUX
- ERBITUX treatment should be stopped if breathing symptoms worsen, and should not be restarted if lung disease is diagnosed
ERBITUX with platinum-based chemotherapy and fluorouracil (CT) was shown to help some people live longer without their cancer growing or spreading compared to CT alone.
Median progression-free survival
Some people who received ERBITUX with CT lived 5.5 months without their cancer growing or spreading compared to 3.3 months with CT alone (median progression-free survival).
The safety and effectiveness of ERBITUX are different for everyone. Individual results may vary. Your doctor is the best person to talk to about ERBITUX, what it may offer, and whether it’s the right treatment option for you.